222 related articles for article (PubMed ID: 35802825)
1. Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease.
Abdelmoaty MM; Machhi J; Yeapuri P; Shahjin F; Kumar V; Olson KE; Mosley RL; Gendelman HE
Clin Transl Med; 2022 Jul; 12(7):e958. PubMed ID: 35802825
[TBL] [Abstract][Full Text] [Related]
2. An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers.
Olson KE; Abdelmoaty MM; Namminga KL; Lu Y; Obaro H; Santamaria P; Mosley RL; Gendelman HE
Transl Neurodegener; 2023 May; 12(1):26. PubMed ID: 37217980
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease.
Olson KE; Namminga KL; Lu Y; Schwab AD; Thurston MJ; Abdelmoaty MM; Kumar V; Wojtkiewicz M; Obaro H; Santamaria P; Mosley RL; Gendelman HE
EBioMedicine; 2021 May; 67():103380. PubMed ID: 34000620
[TBL] [Abstract][Full Text] [Related]
4. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
5. Development of an extended half-life GM-CSF fusion protein for Parkinson's disease.
Yeapuri P; Olson KE; Lu Y; Abdelmoaty MM; Namminga KL; Markovic M; Machhi J; Mosley RL; Gendelman HE
J Control Release; 2022 Aug; 348():951-965. PubMed ID: 35738463
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human granulocyte macrophage-colony stimulating factor expressed in yeast (sargramostim): A potential ally to combat serious infections.
Damiani G; McCormick TS; Leal LO; Ghannoum MA
Clin Immunol; 2020 Jan; 210():108292. PubMed ID: 31676420
[TBL] [Abstract][Full Text] [Related]
7. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages.
O'Mahony DS; Pham U; Iyer R; Hawn TR; Liles WC
Int J Med Sci; 2008 Jan; 5(1):1-8. PubMed ID: 18219369
[TBL] [Abstract][Full Text] [Related]
8. Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth L; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853
[TBL] [Abstract][Full Text] [Related]
9. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.
Wijeyekoon RS; Kronenberg-Versteeg D; Scott KM; Hayat S; Kuan WL; Evans JR; Breen DP; Cummins G; Jones JL; Clatworthy MR; Floto RA; Barker RA; Williams-Gray CH
Brain Behav Immun; 2020 Jul; 87():473-488. PubMed ID: 32006615
[TBL] [Abstract][Full Text] [Related]
10. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.
Joshi I; Carney WP; Rock EP
Front Immunol; 2023; 14():1130214. PubMed ID: 36825018
[TBL] [Abstract][Full Text] [Related]
11. An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation.
Hohenhaus DM; Schaale K; Le Cao KA; Seow V; Iyer A; Fairlie DP; Sweet MJ
Immunobiology; 2013 Nov; 218(11):1345-53. PubMed ID: 23948647
[TBL] [Abstract][Full Text] [Related]
12. Engineering superactive granulocyte macrophage colony-stimulating factor transferrin fusion proteins as orally-delivered candidate agents for treating neurodegenerative disease.
Heinzelman P; Priebe MC
Biotechnol Prog; 2015; 31(3):668-77. PubMed ID: 25737095
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass.
Börgermann J; Friedrich I; Scheubel R; Kuss O; Lendemans S; Silber RE; Kreuzfelder E; Flohé S
Thorac Cardiovasc Surg; 2007 Feb; 55(1):24-31. PubMed ID: 17285470
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor, but not macrophage colony-stimulating factor, suppresses basal and lipopolysaccharide-stimulated complement factor production in human monocytes.
Høgåsen AK; Hestdal K; Abrahamsen TG
J Immunol; 1993 Sep; 151(6):3215-24. PubMed ID: 7690797
[TBL] [Abstract][Full Text] [Related]
16. Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM; Ross M; Vredenburgh J; Meisenberg B; Hars V; Gilbert C; Petros WP; Coniglio D; Kurtzberg J; Rubin P
Eur J Haematol; 1995 May; 54(5):281-7. PubMed ID: 7781752
[TBL] [Abstract][Full Text] [Related]
17. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes.
Hamilton JA; Whitty GA; Stanton H; Wojta J; Gallichio M; McGrath K; Ianches G
Blood; 1993 Dec; 82(12):3616-21. PubMed ID: 8260700
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer.
Nemunaitis J; Nemunaitis J
Clin Lung Cancer; 2003 Nov; 5(3):148-57. PubMed ID: 14667270
[TBL] [Abstract][Full Text] [Related]
19. Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.
Seldon PM; Giembycz MA
Br J Pharmacol; 2001 Sep; 134(1):58-67. PubMed ID: 11522597
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
